A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PDE3A

Search Conditions:
Search Keyword : PDE3A
Search Method : Exact match.
Research Area:

Abbreviation: PDE3A
Appearance Frequency: 65 time(s)
Long forms: 8

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
phosphodiesterase 3A
(57 times)
(11 times)
cAMP (11 times)
PDE3 (5 times)
PKA (5 times)
2000 Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis.
phosphodiesterase type 3A
(2 times)
Cell Biology
(2 times)
cAMP (1 time)
CFTR (1 time)
MIL (1 time)
2010 Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.
partial degradation of cGMP-hydrolyzing phosphodiesterase-3A
(1 time)
(1 time)
cAMP (1 time)
cGMP (1 time)
HF (1 time)
2021 Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia.
PDE, namely phosphodiesterase 3A
(1 time)
Cell Biology
(1 time)
ANP (1 time)
cGMP (1 time)
ER (1 time)
2017 Distinct phosphodiesterase 5A-containing compartments allow selective regulation of cGMP-dependent signalling in human arterial smooth muscle cells.
PDE3 subfamily A
(1 time)
(1 time)
I/R (1 time)
ICEFs (1 time)
PDE3 (1 time)
2015 Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury.
PDE3 were derived from the same gene
(1 time)
(1 time)
--- 1997 Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets.
phosphodiesterase 3A cGMP-inhibited
(1 time)
(1 time)
ACOX1 (1 time)
EWL (1 time)
PRKAB1 (1 time)
2008 Genes and networks expressed in perioperative omental adipose tissue are correlated with weight loss from Roux-en-Y gastric bypass.
pyrazolone derivatives as phosphodiesterase 3A
(1 time)
(1 time)
--- 2017 Docking and quantitative structure-activity relationship of bi-cyclic heteroaromatic pyridazinone and pyrazolone derivatives as phosphodiesterase 3A (PDE3A) inhibitors.